These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
106 related articles for article (PubMed ID: 11374993)
1. Design and synthesis of a conformationally restricted trans peptide isostere based on the bioactive conformations of saquinavir and nelfinavir. Edmonds MK; Abell AD J Org Chem; 2001 Jun; 66(11):3747-52. PubMed ID: 11374993 [TBL] [Abstract][Full Text] [Related]
2. Prodrugs of HIV protease inhibitors-saquinavir, indinavir and nelfinavir-derived from diglycerides or amino acids: synthesis, stability and anti-HIV activity. Gaucher B; Rouquayrol M; Roche D; Greiner J; Aubertin AM; Vierling P Org Biomol Chem; 2004 Feb; 2(3):345-57. PubMed ID: 14747863 [TBL] [Abstract][Full Text] [Related]
3. Synthesis of new thienyl ring containing HIV-1 protease inhibitors: promising preliminary pharmacological evaluation against recombinant HIV-1 proteases. Bonini C; Chiummiento L; De Bonis M; Di Blasio N; Funicello M; Lupattelli P; Pandolfo R; Tramutola F; Berti F J Med Chem; 2010 Feb; 53(4):1451-7. PubMed ID: 20108932 [TBL] [Abstract][Full Text] [Related]
4. [Current status of HIV protease inhibitors]. Yang QG; He XC; Bai DL Yao Xue Xue Bao; 2005 May; 40(5):389-94. PubMed ID: 16220778 [No Abstract] [Full Text] [Related]
5. Design and synthesis of novel conformationally restricted HIV protease inhibitors. Salituro FG; Baker CT; Court JJ; Deininger DD; Kim EE; Li B; Novak PM; Rao BG; Pazhanisamy S; Porter MD; Schairer WC; Tung RD Bioorg Med Chem Lett; 1998 Dec; 8(24):3637-42. PubMed ID: 9934485 [TBL] [Abstract][Full Text] [Related]
6. Asymmetric synthesis of the potent HIV-protease inhibitor, nelfinavir. Raghavan S; Krishnaiah V; Sridhar B J Org Chem; 2010 Jan; 75(2):498-501. PubMed ID: 20000659 [TBL] [Abstract][Full Text] [Related]
7. Enantioselective Synthesis of Nelfinavir via Asymmetric Bromocyclization of Bisallylic Amide. Nagao Y; Hisanaga T; Utsumi T; Egami H; Kawato Y; Hamashima Y J Org Chem; 2018 Jul; 83(13):7290-7295. PubMed ID: 29480721 [TBL] [Abstract][Full Text] [Related]
8. [Novel synthesis and spectral characterization of nelfinavir]. Yan JH; Yao GW; Yang LN; Hu GF; Yang XL Guang Pu Xue Yu Guang Pu Fen Xi; 2008 Jan; 28(1):98-102. PubMed ID: 18422128 [TBL] [Abstract][Full Text] [Related]
9. Stereocontrolled synthesis and biological activity of two diastereoisomers of the potent HIV-1 protease inhibitor saquinavir. Righi G; Ciambrone S; Bonini C; Campaner P Bioorg Med Chem; 2008 Jan; 16(2):902-8. PubMed ID: 17964171 [TBL] [Abstract][Full Text] [Related]
10. Synthesis of poly(ethylene glycol)-based saquinavir prodrug conjugates and assessment of release and anti-HIV-1 bioactivity using a novel protease inhibition assay. Gunaseelan S; Debrah O; Wan L; Leibowitz MJ; Rabson AB; Stein S; Sinko PJ Bioconjug Chem; 2004; 15(6):1322-33. PubMed ID: 15546199 [TBL] [Abstract][Full Text] [Related]
12. Stereoselective synthesis of non symmetric dihydroxyethylene dipeptide isosteres via epoxy alcohols derived from alpha-amino acids. Benedetti F; Magnan M; Miertus S; Norbedo S; Parat D; Tossi A Bioorg Med Chem Lett; 1999 Oct; 9(20):3027-30. PubMed ID: 10571169 [TBL] [Abstract][Full Text] [Related]
13. Asymmetric synthesis of chiral organofluorine compounds: use of nonracemic fluoroiodoacetic acid as a practical electrophile and its application to the synthesis of monofluoro hydroxyethylene dipeptide isosteres within a novel series of HIV protease inhibitors. Myers AG; Barbay JK; Zhong B J Am Chem Soc; 2001 Aug; 123(30):7207-19. PubMed ID: 11472148 [TBL] [Abstract][Full Text] [Related]
14. Virological efficacy and plasma drug concentrations of nelfinavir plus saquinavir as salvage therapy in HIV-infected patients refractory to standard triple therapy. Reiser M; Salzberger B; Stiepel A; Hoetelmans R; Diehl V; Fätkenheuer G Eur J Med Res; 1999 Feb; 4(2):54-8. PubMed ID: 10066640 [TBL] [Abstract][Full Text] [Related]
15. A process in need is a process indeed: scalable enantioselective synthesis of chiral compounds for the pharmaceutical industry. Ikunaka M Chemistry; 2003 Jan; 9(2):378-88. PubMed ID: 12532286 [TBL] [Abstract][Full Text] [Related]
16. Stereoisomers of cyclic urea HIV-1 protease inhibitors: synthesis and binding affinities. Kaltenbach RF; Nugiel DA; Lam PY; Klabe RM; Seitz SP J Med Chem; 1998 Dec; 41(25):5113-7. PubMed ID: 9836627 [TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic interactions between HIV-1 protease inhibitors in rats: study on combinations of two kinds of HIV-1 protease inhibitors. Shibata N; Matsumura Y; Okamoto H; Kawaguchi Y; Ohtani A; Yoshikawa Y; Takada K J Pharm Pharmacol; 2000 Oct; 52(10):1239-46. PubMed ID: 11092568 [TBL] [Abstract][Full Text] [Related]
18. In-vitro and in-vivo pharmacokinetic interactions of amprenavir, an HIV protease inhibitor, with other current HIV protease inhibitors in rats. Shibata N; Gao W; Okamoto H; Kishida T; Yoshikawa Y; Takada K J Pharm Pharmacol; 2002 Feb; 54(2):221-9. PubMed ID: 11848286 [TBL] [Abstract][Full Text] [Related]
19. Structural Basis of Why Nelfinavir-Resistant D30N Mutant of HIV-1 Protease Remains Susceptible to Saquinavir. Prashar V; Bihani SC; Ferrer JL; Hosur MV Chem Biol Drug Des; 2015 Sep; 86(3):302-8. PubMed ID: 25487655 [TBL] [Abstract][Full Text] [Related]